SCHEMBL1708495

SCHEMBL1708495

CS(=O)(=O)Nc1ccccc1Nc1nc(Nc2ccccc2OC(F)F)ncc1Br

nearest known ligand 0.58

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
EGFR P00533 10/20 0.58
ULK1 O75385 1/20 0.56
LRRK2 Q5S007 3/20 0.55
GLO1 Q04760 2/20 0.49
ZAP70 P43403 2/20 0.48
IGF1R P08069 1/20 0.47
GSK3A P49840 1/20 0.47
MAPK15 Q8TD08 1/20 0.47
CAMKK2 Q96RR4 1/20 0.47
CDK19 Q9BWU1 1/20 0.46
ALK Q9UM73 1/20 0.46
MET P08581 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9911241 0.87 EGFR (0.69) EGFRULK1LRRK2ZAP70IGF1R
Hydrochloric Acid SCHEMBL1708532 0.86 EGFR (0.68) EGFRULK1LRRK2ZAP70IGF1R
SCHEMBL1039207 0.85 GLO1 (0.55) EGFRULK1GLO1ZAP70IGF1R
SCHEMBL9911237 0.83 GLO1 (0.60) EGFRLRRK2GLO1ZAP70IGF1R
Hydrochloric Acid SCHEMBL1706957 0.82 GLO1 (0.59) EGFRLRRK2GLO1ZAP70IGF1R
SCHEMBL1707650 0.82 EGFR (0.63) EGFRULK1LRRK2ZAP70CDK19
SCHEMBL9911244 0.82 EGFR (0.57) EGFRLRRK2GLO1ZAP70IGF1R
SCHEMBL9911240 0.81 EGFR (0.56) EGFRGLO1ZAP70IGF1RALK
Hydrochloric Acid SCHEMBL1706872 0.81 EGFR (0.56) EGFRLRRK2GLO1ZAP70IGF1R
SCHEMBL9911238 0.81 IGF1R (0.74) EGFRLRRK2GLO1IGF1RCDK19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142667-A1 PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS CELLZOME LIMITED (GB) 2012-06-07 US claimed
EP-2440534-A2 PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS Cellzome Limited (GB) 2012-04-18 EP claimed
WO-2010142766-A2 PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS CELLZOME LIMITED (GB) 2010-12-16 WO claimed
US-20120142667-A1 PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS CELLZOME LIMITED (GB) 2012-06-07 US disclosed
US-20120142667-A1 PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS CELLZOME LIMITED (GB) 2012-06-07 US disclosed
US-20120142667-A1 PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS CELLZOME LIMITED (GB) 2012-06-07 US disclosed
EP-2440534-A2 PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS Cellzome Limited (GB) 2012-04-18 EP disclosed
WO-2010142766-A2 PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS CELLZOME LIMITED (GB) 2010-12-16 WO disclosed
WO-2010142766-A2 PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS CELLZOME LIMITED (GB) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142667-A1 PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS ZAP70, LCK, DPY30 EGFR 3420/4885ULK1 2633/4885LRRK2 3072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.